tbuckley/cabot-search huggingface dataset:
PATH-64. PROSPECTIVE, BLINDED PLASMA BASED ANALYSIS FOR DIAGNOSIS OF NEWLY DIAGNOSED GLIOMA
Authors: Ian Lee, Lisa Scarpace, Rachel Hunt, Kevin Nelson, Darshana Patil, Vineet Datta, Dadasaheb Akolkar, Sachin Apurva, Pooja Fulmali, Sneha Puranik, James Snyder, Houtan Noushmehr, Pradeep Devhare, Ana deCarvalho, Rajan Datar, Tobias Walbert, Steven Kalkanis
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION In patients with newly diagnosed intracerebral lesions, gliomas are often suspected. However, other conditions such as multiple sclerosis, abscess or lymphoma are possible, as well. Furthermore, biopsy can be challenging due to eloquent and/or deep location within the brain. In this prospective, blinded study, analysis of plasma isolated cell-free DNA and exosome mRNA and miRNA from newly diagnosed glioma patients and from cancer-free volunteers was used to predict disease. METHODS Plasma was drawn from 52 patients with newly diagnosed gliomas (28 high grade glioma (HGG), 10 low grade (LGG)) and 14 patients without documented history of cancer and recent MRI brain which was negative for brain tumor. High quality DNA and RNA was isolated and sequenced using Next Generation Sequencing and Digital Droplet PCR was used for detection and verification of trace molecular artifacts. Multianalyte processing yielded data that was harmonized and interpreted through an Artificial Intelligence based algorithm to assess for possible glioma and to assign grade in a blinded fashion. EGFRvIII, TP53 and IDH1 mutations were also analyzed and compared to molecular testing from tumor specimens. RESULTS 66% (25 of 38) of glioma patients were correctly diagnosed as having a malignancy. 43% of HGG and 60% of LGG patients were correctly graded. Of the 14 normal controls, 6 were concluded to be cancer-free. IDH1, EGFRvIII, and TP53 mutation had concordance of 64% (21/33), 82% (14/17) and 36% (5/14), respectively. CONCLUSIONS Analysis of plasma cell free tumor derived DNA and RNA was relatively sensitive for detecting glioma in treatment naïve patients. In contrast, this analysis was not specific in ruling out malignancy in the normal control patients. Given this profile, in patients with newly diagnosed intracerebral lesions suspicious for glioma, this may be a useful screening test to determine the need for more invasive testing, i.e. biopsy/resection.
Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis
Authors: Ashwin Gupta, Abdul Hannan, Ruby Maini, Stephanie Bitner, Schuyler Stone, Manjari Regmi, Aaron Tobian, Cassandra D Josephson, Lakshmanan Krishnamurti, Clifford M. Takemoto, Ruchika Goel
Journal: Blood (2019)
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
Authors: Guillermo Montalban-Bravo, Caleb A. Class, Irene Ganan-Gomez, Rashmi Kanagal-Shamanna, Koji Sasaki, Guillaume Richard-Carpentier, Kiran Naqvi, Yue Wei, Hui Yang, Kelly A. Soltysiak, Kelly Chien, Carlos Bueso-Ramos, Kim-Anh Do, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Leukemia (2019)
Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice
Authors: Kathryn Richert-Boe, Lois Lamerato, Gary H. Lyman, Manpreet Kaur, Neel Shah, Tatiana Lawrence, Devi Sundaresan, Amanda Silvia, Ahuva Hanau, Derek Weycker
Journal: Blood (2019)
Germline Variation Predicts Treatment Response in Multiple Myeloma
Authors: Kyle Roter, Donglei Hu, Alyssa Clay-Gilmour, Scott Huntsman, Nina D. Shah, Sandy W. Wong, Thomas G. Martin, Jeffrey Lee Wolf, Moritz Binder, Shaji K. Kumar, S. Vincent Rajkumar, Susan L. Slager, Celine M. Vachon, Elad Ziv
Journal: Blood (2019)
CysLT1R expression on ILC2s and effects of CysLT1R antagonist on ILC2 activity in patients with allergic rhinitis
Authors: Zi‐Li Qin, Ya‐Qi Peng, Shu‐Bin Fang, Ai‐Yun Jiang, Cheng‐Lin Li, Xing‐Liang Fan, Dong Chen, Wen‐Na Chen, Joseph.A. Bellanti, Song Guo Zheng, Qing‐Ling Fu
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma
Authors: Francis K. Buadi, Martha Q. Lacy, Betsy Laplant, Eric Wolfe, Morie A. Gertz, Sikander Ailawadhi, Suzanne R. Hayman, Ronald S. Go, Dania Kaehlyn Helgeson, Vivek Roy, Craig B. Reeder, Amie Fonder, Yi L. Hwa, Miriam A. Hobbs, P. Leif Bergsagel, Rafael Fonseca, David Dingli, Wilson I Gonsalves, Prashant Kapoor, Asher A. Chanan-Khan, Taxiarchis Kourelis, Jeremy Larsen, Stephen J Russell, John A. Lust, Taimur Sher, Mustaqeem A. Siddiqui, A. Keith Stewart, Rahma M Warsame, S. Vincent Rajkumar, Robert A. Kyle, Shaji K. Kumar
Journal: Blood (2019)
Pernicious Anemia in Childhood
Authors: Thomas D. Stevenson, Joseph A. Little, Leslie Langley
Journal: New England Journal of Medicine (1956)

THE clinical and hematologic manifestations of pernicious anemia are due to a deficiency of vitamin B12 resulting from a specific and selective inability to absorb the vitamin from the gastrointestinal tract. The failure of absorption of vitamin B12 in pernicious anemia is due to the absence of intrinsic factor from the gastric secretion that is associated with, and generally considered to result from, atrophy of the gastric mucosa.1 Achylia gastrica accompanies the atrophy of the gastric mucosa, and free hydrochloric acid is rarely present in the gastric secretion.Vitamin B12 deficiency can be proved by serum microbiologic . . .
Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest
Authors: Bruno François, Alain Cariou, Raphaël Clere-Jehl, Pierre-François Dequin, Françoise Renon-Carron, Thomas Daix, Christophe Guitton, Nicolas Deye, Stéphane Legriel, Gaëtan Plantefève, Jean-Pierre Quenot, Arnaud Desachy, Toufik Kamel, Sandrine Bedon-Carte, Jean-Luc Diehl, Nicolas Chudeau, Elias Karam, Isabelle Durand-Zaleski, Bruno Giraudeau, Philippe Vignon, Amélie Le Gouge
Journal: New England Journal of Medicine (2019)

Patients who are treated with targeted temperature management after out-of-hospital cardiac arrest with shockable rhythm are at increased risk for ventilator-associated pneumonia. The benefit of preventive short-term antibiotic therapy has not been shown.
Silent Cerebral Infarcts in Sickle Cell Disease: A Systematic Review
Authors: Maite E. Houwing, Rowena Grohssteiner, Anne P.J. de Pagter, Karin Fijnvandraat, Jaap Oosterlaan, Lotte Haverman, Marjolein Dremmen, Tonya White, Marjon H. Cnossen
Journal: Blood (2019)
Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers
Authors: Joanne Davis, Sasanka M Handunnetti, Chia Sharpe, Gillian Turner, Mary Ann Anderson, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, David Ritchie, Rachel Koldej
Journal: Blood (2019)
C/EBPβ Isoforms Regulate Proliferation and Differentiation of Regenerating Hematopoietic Stem/Progenitor Cells
Authors: Atsushi Sato, Asumi Yokota, Yoshihiro Hayashi, Naoka Kamio, Satoshi Sagai, Taira Maekawa, Hideyo Hirai
Journal: Blood (2019)
Trefoil Factor Family 1 Inhibits the Development of Hepatocellular Carcinoma by Regulating β‐Catenin Activation
Authors: Yosuke Ochiai, Junpei Yamaguchi, Toshio Kokuryo, Yukihiro Yokoyama, Tomoki Ebata, Masato Nagino
Journal: Hepatology (2019)

Background and Aims Recent studies have suggested that trefoil factor family 1 (TFF1) functions as a tumor suppressor in gastric and pancreatic carcinogenesis. Approach and Results To investigate the role of TFF1 in hepatocarcinogenesis, we performed immunohistochemical staining of surgically resected human liver samples, transfected a TFF1 expression vector into hepatocellular carcinoma (HCC) cell lines, and employed a mouse model of spontaneous HCC development (albumin–cyclization recombination/Lox‐Stop‐Lox sequence–Kirsten rat sarcoma viral oncogene homolog G12D [KC]); the model mouse strain was bred with a TFF1‐knockout mouse strain to generate a TFF1‐deficient HCC mouse model (KC/TFF1 −/− ). TFF1 expression was found in some human samples with HCC. Interestingly, TFF1‐positive cancer cells showed a staining pattern contradictory to that of proliferating cell nuclear antigen, and aberrant DNA hypermethylation in TFF1 promoter lesions was detected in HCC samples, indicating the tumor‐suppressive role of TFF1. In vitro , induction of TFF1 expression resulted in impaired proliferative activity and enhanced apoptosis in HCC cell lines (HuH7, HepG2, and HLE). These anticancer effects of TFF1 were accompanied by the loss of nuclear β‐catenin expression, indicating inactivation of the β‐catenin signaling pathway by TFF1 . In vivo , TFF1 deficiency in KC mice accelerated the early development and growth of HCC, resulting in poor survival rates. In addition, immunohistochemistry revealed that the amount of nuclear‐localized β‐catenin was significantly higher in KC/TFF1 −/− mice than in KC mice and that human HCC tissue showed contradictory expression patterns for β‐catenin and TFF1, confirming the in vitro observations. Conclusions TFF1 might function as a tumor suppressor that inhibits the development of HCC by regulating β‐catenin activity.
Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity
Authors: Ashwin Kishtagari, Hassan Awada, Reda Z. Mahfouz, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, Bhumika J. Patel, Valeria Visconte, Tomas Radivoyevitch, Alan Lichtin, MD, Hetty E. Carraway, Jaroslaw P. Maciejewski, Yogenthiran Saunthararajah
Journal: Blood (2019)
Epigenetic Silencing of Mir-203 Contributes to IL2Rb Overexpression and Malignant Transformation in Cutaneous T-Cell Lymphoma
Authors: Ulrik Ralfkiaer, Martin Jansson, Katharina Kopp, Andreas Willerslev-Olsen, Fazila Asmar, Thorbjorn Krejsgaard, Peter de Nully Brown, Robert Gniadecki, Anders Woetman, Anders Lund, Niels Odum, Kirsten Groenbaek
Journal: Blood (2014)
Progress Toward Poliomyelitis Eradication — Pakistan, January 2018–September 2019
Authors: Christopher H. Hsu, Milhia Kader, Abdirahman Mahamud, Kelley Bullard, Jaume Jorba, John Agbor, Malik Muhammad Safi, Hamid S. Jafari, Derek Ehrhardt
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Afghanistan and Pakistan are the only countries that continue to confirm ongoing wild poliovirus type 1 (WPV1) transmission (1). During January 2018-September 2019 the number of WPV1 cases in Pakistan increased, compared with the number during the previous 4 years. This report updates previous reports on Pakistan's polio eradication activities, progress, and challenges (2,3). In 2018, Pakistan reported 12 WPV1 cases, a 50% increase from eight cases in 2017, and a 31% increase in the proportion of WPV1-positive sites under environmental surveillance (i.e., sampling of sewage to detect poliovirus). As of November 7, 2019, 80 WPV1 cases had been reported, compared with eight cases by the same time in 2018. An intensive schedule of supplementary immunization activities (SIAs)* implemented by community health workers in the core reservoirs (i.e., Karachi, Peshawar, and Quetta) where WPV1 circulation has never been interrupted, and by mobile teams, has failed to interrupt WPV1 transmission in core reservoirs and prevent WPV1 resurgence in nonreservoir areas. Sewage samples have indicated wide WPV1 transmission in nonreservoir areas in other districts and provinces. Vaccine refusals, chronically missed children, community campaign fatigue, and poor vaccination management and implementation have exacerbated the situation. To overcome challenges to vaccinating children who are chronically missed in SIAs and to attain country and global polio eradication goals, substantial changes are needed in Pakistan's polio eradication program, including continuing cross-border coordination with Afghanistan, gaining community trust, conducting high-quality vaccination campaigns, improving oversight of field activities, and improving managerial processes to unify eradication efforts.
Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification
Authors: Bernice Oh, Shawn Lee, Zelia Seeto, Germaine Liew, Edwynn Chiew, Zhi Wei Chen, Yiong Huak Chan, Jing Jia Eng, Koon Mian Foo, Ching Mei Joyce Lam, Ah Moy Tan, Allen Eng Juh Yeoh
Journal: Blood (2019)
DDIS-24. DECREASE IN GLIOBLASTOMA GROWTH IN VITRO WITH TREATMENT OF NOVEL ANALOGS OF GLUCOSE TRANSPORTER INHIBITORS
Authors: Sajina GC, Catherine Libby, Sixue Zhang, Gloria Benavides, Sarah Scott, Yanjie Li, Anh Tran, Arphaxad Otamias, Victor Darley-Usmar, Marek Napierala, Vibha Pathak, Omar Moukha-Chafiq, Corinne Augelli-Szafran, Wei Zhang, Anita Hjelmeland
Journal: Neuro-Oncology (2019)

Abstract Despite available treatments including surgical resection, radiation and chemotherapy, glioblastoma (GBM) is incurable with rapid recurrence and low median survival rate of just fourteen months. Development of more effective treatments is difficult due to the highly heterogeneous nature of GBM. One aspect of that heterogeneity involves brain tumor initiating cells (BTICs) that have a stem cell-like ability to self-renew. BTICs can readily alter their metabolism and survive in low nutrient environments due in part to increased GLUT3 expression. We believe that the higher expression of GLUT3 in cancer cells compared to non-tumor cells makes it a therapeutic target, although the potential for toxicity must be considered. In recently accepted studies by Libby et al., we reported on two novel GLUT inhibitors identified by structure based virtual screening (SBVS) using a GLUT3 homology model. We are creating a structure-activity relationship profile and seek to increase the potency, selectivity and stability of the GLUT inhibitors. In this study we have tested a number of novel analogs and identified three that have maintained efficacy against BTICs in vitro. Importantly, these compounds display minimal toxicity against human astrocytes. The novel derivatives have increased stability compared to the lead compounds and are efficacious in the nanomolar range. In the future, we intend to utilize our anti-GLUT compounds alone and in combination with radio- and chemotherapy with the hope of clinical translation.
Epigenetic <i>SMAD3</i> Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma
Authors: Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso, Paloma Bragado, Marselina Arshakyan, Iuliana-Cristiana Luis, Albert Marín, Sebastian Morán, Manuel Castro, Gemma Fuster, Sabrina Gea-Sorli, Toni Jauset, Laura Soucek, Luis M. Montuenga, Manel Esteller, Eduard Monsó, Victor Ivo Peinado, Pere Gascon, Cristina Fillat, Frank Hilberg, Noemí Reguart, Jordi Alcaraz
Journal: Cancer Research (2019)

Abstract The tumor-promoting fibrotic stroma rich in tumor-associated fibroblasts (TAF) is drawing increased therapeutic attention. Intriguingly, a trial with the antifibrotic drug nintedanib in non–small cell lung cancer reported clinical benefits in adenocarcinoma (ADC) but not squamous cell carcinoma (SCC), even though the stroma is fibrotic in both histotypes. Likewise, we reported that nintedanib inhibited the tumor-promoting fibrotic phenotype of TAFs selectively in ADC. Here we show that tumor fibrosis is actually higher in ADC-TAFs than SCC-TAFs in vitro and patient samples. Mechanistically, the reduced fibrosis and nintedanib response of SCC-TAFs was associated with increased promoter methylation of the profibrotic TGFβ transcription factor SMAD3 compared with ADC-TAFs, which elicited a compensatory increase in TGFβ1/SMAD2 activation. Consistently, forcing global DNA demethylation of SCC-TAFs with 5-AZA rescued TGFβ1/SMAD3 activation, whereas genetic downregulation of SMAD3 in ADC-TAFs and control fibroblasts increased TGFβ1/SMAD2 activation, and reduced their fibrotic phenotype and antitumor responses to nintedanib in vitro and in vivo. Our results also support that smoking and/or the anatomic location of SCC in the proximal airways, which are more exposed to cigarette smoke particles, may prime SCC-TAFs to stronger SMAD3 epigenetic repression, because cigarette smoke condensate selectively increased SMAD3 promoter methylation. Our results unveil that the histotype-specific regulation of tumor fibrosis in lung cancer is mediated through differential SMAD3 promoter methylation in TAFs and provide new mechanistic insights on the selective poor response of SCC-TAFs to nintedanib. Moreover, our findings support that patients with ADC may be more responsive to antifibrotic drugs targeting their stromal TGFβ1/SMAD3 activation. Significance: This study implicates the selective epigenetic repression of SMAD3 in SCC-TAFs in the clinical failure of nintedanib in SCC and supports that patients with ADC may benefit from antifibrotic drugs targeting stromal TGFβ1/SMAD3.
Longitudinal changes in airway hyperresponsiveness and COPD mortality
Authors: Andreas A. Teferra, Judith M. Vonk, H. Marike Boezen
Journal: European Respiratory Journal (2019)

Airway hyperresponsiveness (AHR) is associated with an increased mortality risk among males [1] and chronic obstructive pulmonary disease (COPD) patients [2]. However, this association is largely based on cross-sectional studies using a single measurement of AHR to predict mortality; inherently ignoring the longitudinal variability of AHR. AHR is variable regardless of disease or medication status, and is linked with changes in smoking habits, seasonal variations and exposure to pollutants [3–5]. Considering this, it remains unclear how changes in AHR affect mortality, specifically from causes such as COPD, cardiovascular disease (CVD) and cancer. Airway hyperresponsiveness displayed on multiple occasions independently leads to a higher risk of COPD death <http://bit.ly/363Wfkg> The authors would like to thank Statistics Netherlands (CBS) for providing access to vital status data for the participants. We also want to thank Douwe Postmus and Hans Burgerhof (Dept of Epidemiology, University of Groningen, Groningen, the Netherlands) for providing valuable statistical advice.
An HPFH Mutation in the γ-Globin Gene Promoter of Humanized Cooley's Anemia Mice Rescues Them from Perinatal Lethality and Renders Them Transfusion Independent
Authors: Suean Daimia Fontenard, Yongliang Huo, Shanrun Liu, Jonathan Lockhart, Michael Berlett, Thomas M Ryan
Journal: Blood (2016)
Multifocal Urinary Bladder Paragangliomas With Negative 68Ga-DOTATATE Uptake and Positive 123I-MIBG Uptake
Authors: Laura A. Parra, Scott K. Swanson, Marcela A. Salomao, Ming Yang
Journal: Clinical Nuclear Medicine (2019)

We report a case of an adult male patient with multifocal urinary bladder paragangliomas, which were negative on Ga-DOTATATE PET/CT scan, but positive on I-MIBG SPECT/CT scan. While the Ga-DOTA analog PET/CT exhibits superior performance in diagnosis and staging of pheochromocytoma and paraganglioma, our case demonstrates negative somatostatin receptor expression in this rare entity and indicates that I-MIBG SPECT/CT still plays a vital role in characterization of bladder paraganglioma.
Emigration of Doctors
Authors: K. I. E. Macleod
Journal: BMJ (1964)

for the necessary provision of money and also oversee its prudent expenditure, but one might reasonably hope that the release from fear of local political control by the derivation of income directly from their patients, and the uniformity of mode of income, would gradually lead to the reintegration of medical practice as part-general and part-specialized according to local needs and personal abilities.-I am, etc., Hull.
Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)
Authors: Eduardo Sobejano, Veronica Gonzalez De La Calle, Victor Higuero, Fernando Escalante, Ramón García-Sanz, Daniel Presa, Raul Azibeiro, Marta Fonseca, Beatriz Rey, Noemi Puig, Norma C. Gutierrez, Pilar Leóz, Jorge Labrador, Carmen Aguilera, Jose Maria Alonso Alonso, Rosa López, Aránzazu García Mateo, Alfonso Garcia, Roberto Hernández, Abelardo Barez Garcia, Julio Dávila, Elena Redondo, Victor Quirós, María-Victoria Mateos
Journal: Blood (2019)
Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase
Authors: Sarah P. Suehnholz, Ritika Kundra, Mikhail Roshal, Wenbin Xiao, Kseniya Petrova-Drus, Mariko Yabe, Caleb Ho, Hongxin Zhang, David Knorr, Linde A Miles, Scott Millman, Moriah H. Nissan, Lindsay M. LaFave, Maria E Arcila, Michael F. Berger, Ahmet Zehir, Ryan Ptashkin, Jianjiong Gao, David B. Solit, Ahmet Dogan, Ross L. Levine, Nikolaus Schultz, Debyani Chakravarty
Journal: Blood (2019)
Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry
Authors: Thibault Comont, Natacha Brun, Johanne Germain, Claire Dingremont, Brice Castel, Sophie Arista, Serge Madaule, Phillipe Montané de la Roque, Laurent Prudhomme, Laurent Sailler, Laurent Balardy, Laurent Alric, Christian Recher, Miguel Carreiro, Francis Gaches, Maryse Lapeyre-Mestre, Odile Beyne-Rauzy, Daniel Adoue, Guillaume Moulis, Carmen investigators Group
Journal: Blood (2019)
Virological and Immunological Monitoring of Human Cytomegalovirus (HCMV) Infection in Hematopoietic Stem Cell Transplantation Recipients (HSCTR)
Authors: Elisa Gabanti, Roberta Sciarra, Oscar Borsani, Giuseppe Gerna, Daniela Caldera, Anna Amelia Colombo, Emilio Paolo Alessandrino, Paolo Bernasconi, Daniele Lilleri
Journal: Blood (2019)
Two Distinct Subsets of dic(9;12)(p12;p11.2) among Children with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL): PAX5-ETV6 and ETV6-RUNX1 Rearrangements: A Report from the Children’s Oncology Group.
Authors: Julie M. Gastier-Foster, Andrew J. Carroll, Denise Ell, Richard Harvey, I-Ming Chen, Rhett Ketterling, Aurelia Meloni-Ehrig, Kent E. Opheim, Shivanand Patil, Mark Pettenati, Kathleen Rao, ShiQi Wu, Nyla A. Heerema
Journal: Blood (2007)
Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group
Authors: Elena E. Solomou, Alexandra Kourakli, Anna Vardi, Ioannis Kotsianidis, Panagiotis Zikos, Vassiliki Pappa, Athanasios Galanopoulos, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, Panagiotis T Diamantopoulos, Theodoros Vassilakopoulos, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, George Vassilopoulos, Achilles Anagnostopoulos, Argiris Symeonidis
Journal: Blood (2019)
Acute Intussusception in Childhood
Authors: F. Barber
Journal: BMJ (1948)

For these reasons, then, I regard all cases of phantom pain as being similar in origin and mechanism of production, whether they have burning pain or not.It is, however, possibly not altogether desirable for the word " causalgia " to be used to describe all these cases, with their varying painful sensations, or even for the term "minor causalgia " to be used for the less severe examples.As pointed out by Dr. Bowden and Dr. Napier, Weir Mitchell originally coined the word " causalgia," meaning literally " fire pain," to describe only the single symptom of burning pain; and it might still be desirable to use it only in this sense, or at least only for cases with this type of pain, without of course implying that there is any difference in pathogenesis between this " causalgic ' pain and lesser degrees of pain following nerve trauma.-Iam, etc., Belfast.